赛庚啶在儿童消化系统疾病中的应用

doi:10.20274/j.cnki.issn.2025.04.005

摘要/Abstract

摘要：

赛庚啶作为一种具有抗组胺、抗胆碱能和抗5-羟色胺作用的多受体拮抗剂，近年来在儿童功能性胃肠病治疗中显示出良好的疗效和安全性。本文主要阐述了赛庚啶在功能性消化不良、腹型偏头痛、周期性呕吐综合征及神经性厌食症等疾病中的作用机制、临床应用方案和疗效评价，为其在儿童消化系统疾病的临床治疗提供参考依据。未来需要进一步开展前瞻性研究，制定明确的用药指南，促进赛庚啶在儿科领域的合理和规范使用。

关键词: 消化系统疾病, 赛庚啶, 儿童

Abstract:

Cyproheptadine, a multi-receptor antagonist with antihistaminic, anticholinergic, and anti-serotonergic properties, has recently demonstrated favorable efficacy and safety profiles in the treatment of functional gastrointestinal disorders (FGID) in children. This article mainly elaborates on the mechanisms of action, clinical application regimens, and therapeutic evaluations of cyproheptadine in conditions such as functional dyspepsia (FD), abdominal migraine (AM), cyclic vomiting syndrome (CVS), and anorexia nervosa, thereby providing a reference for its clinical use in the treatment of pediatric digestive diseases. Further prospective studies are warranted in the future to establish clear guidelines for its administration in order to promote its rational and standardized application in pediatric diseases.

Key words: Digestive disorders, Cyproheptadine, Child

中图分类号:

R725.7

李子颖, 王跃生, 李小芹. 赛庚啶在儿童消化系统疾病中的应用[J]. 中国中西医结合儿科学, 2025, 17(4): 298-301.

Ziying LI, Yuesheng WANG, Xiaoqin LI. Application of cyproheptadine in digestive disorders in children[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 298-301.

参考文献 40

[1]	Huang Y, Tan SY, Parikh P, et al. Prevalence of functional gastrointestinal disorders in infants and young children in China[J]. BMC Pediatr, 2021, 21(1): 131.
[2]	Steutel NF, Zeevenhooven J, Scarpato E, et al. Prevalence of functional gastrointestinal disorders in European infants and toddlers[J]. J Pediatr, 2020, 221: 107-114.
[3]	Vernon-Roberts A, Alexander I, Day AS. Systematic review of pediatric functional gastrointestinal disorders(Rome Ⅳ criteria)[J]. J Clin Med, 2021, 10(21): 5087.
[4]	邹毅, 张慧华, 刘波, 等. 儿科消化门诊功能性胃肠疾病诊疗现状: 一项单中心的临床报道[J]. 中国实用儿科杂志, 2021, 36(8): 632-636.
[5]	Di Nardo G, Barbara G, Borrelli O, et al. Italian guidelines for the management of irritable bowel syndrome in children and adolescents: joint Consensus from the Italian Societies of: gastroenterology, Hepatology and Pediatric Nutrition (SIGENP), Pediatrics (SIP), Gastroenterology and Endoscopy (SIGE) and Neurogastroenterology and Motility (SINGEM)[J]. Ital J Pediatr, 2024, 50(1): 51.
[6]	张薇, 王宝西. 儿童功能性胃肠病诊治现状[J]. 中国小儿急救医学, 2022, 29(2): 81-85.
[7]	Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa[J]. Expert Opin Pharmacother, 2004, 5(11): 2287-2292.
[8]	Homnick DN, Marks JH, Hare KL, et al. Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis[J]. Pediatr Pulmonol, 2005, 40(3): 251-256.
[9]	Rodriguez L, Diaz J, Nurko S. Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children[J]. J Pediatr, 2013, 163(1): 261-267.
[10]	Merhar SL, Pentiuk SP, Mukkada VA, et al. A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects[J]. Acta Paediatr, 2016, 105(8): 967-970.
[11]	Bertrand V, Massy N, Vegas N, et al. Safety of cyproheptadine, an orexigenic drug. analysis of the French national pharmacovigilance data-base and systematic review[J]. Front Pediatr, 2021, 9: 712413.
[12]	中华医学会儿科学分会消化学组, 中国中药协会儿童健康与药物研究专业委员会消化学组, 中华儿科杂志编辑委员会, 等. 中国儿童功能性消化不良诊断和治疗共识(2022版)[J]. 中华儿科杂志, 2022, 60(8): 751-755.
[13]	Shava U, Srivastava A, Mathias A, et al. Functional dyspepsia in children: a study of pathophysiological factors[J]. J Gastroenterol Hepatol, 2021, 36(3): 680-686.
[14]	O’Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis[J]. Behav Brain Res, 2015, 277: 32-48.
[15]	中国医师协会神经内科医师分会, 中国研究型医院学会头痛与感觉障碍专业委员会. 中国偏头痛诊治指南(2022版)[J]. 中国疼痛医学杂志, 2022, 28(12): 881-898.
[16]	Mortimer MJ, Kay J, Jaron A. Clinical epidemiology of childhood abdominal migraine in an urban general practice[J]. Dev Med Child Neurol, 1993, 35(3): 243-248.
[17]	耿岚岚(译,刘明南(译,龙高(译,等. 儿童功能性胃肠病罗马Ⅳ标准[J]. 中华儿科杂志,2017,55(1):4-14.
[18]	Cheema S, Matharu M. Abdominal migraine and cyclical vomiting syndrome[J]. Handb Clin Neurol, 2023, 198: 209-219.
[19]	Papetti L, Ursitti F, Moavero R, et al. Prophylactic treatment of pediatric migraine: is there anything new in the last decade[J]? Front Neurol, 2019, 10: 771.
[20]	Lewis DW, Diamond S, Scott D, et al. Prophylactic treatment of pediatric migraine[J]. Headache, 2004, 44(3): 230-237.
[21]	Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine[J]. Curr Pain Headache Rep, 2014, 18(6): 422.
[22]	Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine[J]. J Emerg Med, 1998, 16(4): 615-619.
[23]	郭姝, 吴捷. 儿童周期性呕吐综合征的治疗策略[J]. 中国小儿急救医学, 2022, 29(2): 95-98.
[24]	Fitzpatrick E, Bourke B, Drumm B, et al. The incidence of cyclic vomiting syndrome in children: population-based study[J]. Am J Gastroenterol, 2008, 103(4): 991-995.
[25]	Venkatesan T, Prieto T, Barboi A, et al. Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study[J]. Neurogastroenterol Motil, 2010, 22(12): 1303-1307.
[26]	Hasler WL, Levinthal DJ, Tarbell SE, et al. Cyclic vomiting syndrome: pathophysiology, comorbidities, and future research directions[J]. Neurogastroenterol Motil, 2019, 31(): e13607.
[27]	McAbee GN, Morse AM, Cook W, et al. Neurological etiologies and pathophysiology of cyclic vomiting syndrome[J]. Pediatr Neurol, 2020, 106: 4-9.
[28]	Li BUK, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome[J]. J Pediatr Gastroenterol Nutr, 2008, 47(3): 379-393.
[29]	唐硕, 游洁玉, 欧阳文献, 等. 小儿再发性呕吐综合征的临床疗效观察[J]. 中国当代儿科杂志, 2010, 12(12): 993-994.
[30]	罗艳红, 游洁玉. 赛庚啶、胞二磷胆碱治疗小儿周期性呕吐综合征疗效观察[J]. 临床儿科杂志, 2008, 26(10): 847-849.
[31]	Badihian N, Saneian H, Badihian S, et al. Prophylactic therapy of cyclic vomiting syndrome in children: comparison of amitriptyline and cyproheptadine: a randomized clinical trial[J]. Am J Gastroenterol, 2018, 113(1): 135-140.
[32]	Thavamani A, Umapathi KK, Velayuthan S, et al. Burden of psychiatric disorders in patients with cyclic vomiting syndrome - Need for aggressive screening and early intervention[J]. Dig Liver Dis, 2022, 54(2): 287-289.
[33]	Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018[J]? Curr Gastroenterol Rep, 2018, 20(10): 46.
[34]	Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition[J]. Eur J Oncol Nurs, 2005, 9(): S51-63.
[35]	Chakrabarty AS, Pillai RV, Anand BK, et al. Effect of cyproheptadine on the electrical activity of the hypothalamic feeding centres[J]. Brain Res, 1967, 6(3): 561-569.
[36]	Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia[J]. Gut, 2008, 57(11): 1495-1503.
[37]	Najib K, Moghtaderi M, Karamizadeh Z, et al. Beneficial effect of cyproheptadine on body mass index in undernourished children: a randomized controlled trial[J]. Iran J Pediatr, 2014, 24(6): 753-758.
[38]	Harrison ME, Norris ML, Robinson A, et al. Use of cyproheptadine to stimulate appetite and body weight gain: a systematic review[J]. Appetite, 2019, 137: 62-72.
[39]	Sant’Anna AMGA, Hammes PS, Porporino M, et al. Use of cyproheptadine in young children with feeding difficulties and poor growth in a pediatric feeding program[J]. J Pediatr Gastroenterol Nutr, 2014, 59(5): 674-678.
[40]	Badr B, Naguy A. Cyproheptadine : a psychopharmacological treasure trove[J]? CNS Spectr, 2022, 27(5): 533-535.